One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence

K. Benson*, R. McCrery, C. Taylor, O. Padron, B. Blok, S. de Wachter, A. Pezzella, J. Gruenenfelder, M. Pakzad, M.A. Perrouin-Verbe, P. Van Kerrebroeck, J. Mangel, K. Peters, M. Kennelly, A. Shapiro, U. Lee, C. Comiter, M. Mueller, H. Goldman, F. Lane

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Web of Science)


Aims Sacral neuromodulation (SNM) is a guideline-recommended treatment for voiding dysfunction including urgency, urge incontinence, and nonobstructive retention as well as fecal incontinence. The Axonics (R) System is a miniaturized, rechargeable SNM system designed to provide therapy for at least 15 years, which is expected to significantly reduce revision surgeries as it will not require replacement as frequently as the non-rechargeable SNM system. The ARTISAN-SNM study is a pivotal study designed to treat patients with urinary urgency incontinence (UUI). Clinical results at 1-year are presented.Methods A total of 129 eligible UUI patients were treated. All participants were implanted with a quadripolar tined lead and neurostimulator in a single procedure. Efficacy data were collected using a 3-day bladder diary, a validated quality of life questionnaire (ICIQ-OABqol), and a participant satisfaction questionnaire. Therapy responders were defined as participants with >= 50% reduction in UUI episodes compared to baseline. Data were analyzed on all 129 participants.Results At 1 year, 89% of the participants were therapy responders. The average UUI episodes per day reduced from 5.6 +/- 0.3 at baseline to 1.4 +/- 0.2. Participants experienced an overall clinically meaningful improvement of 34 points on the ICIQ-OABqol questionnaire. All study participants (100%) were able to recharge their device at 1 year, and 96% of participants reported that the frequency and duration of recharging was acceptable. There were no serious device-related adverse events.Conclusions The Axonics System is safe and effective at 1 year, with 89% of participants experiencing clinically and statistically significant improvements in UUI symptoms.
Original languageEnglish
Pages (from-to)1482-1488
Number of pages7
JournalNeurourology and Urodynamics
Issue number5
Publication statusPublished - 1 Jun 2020


  • clinical trial
  • implantable neurostimulator
  • overactive bladder
  • placement
  • sacral neuromodulation
  • urinary urgency incontinence

Cite this